This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Malaria Vaccine (GNVC), NMRC-M3V-Ad-PfCA
Drug Names(s): Multi-Antigen Malaria Vaccine
Description: The Multi-Antigen Malaria Vaccine is designed to attack both the blood and liver stages of the malaria parasite. The vaccine candidate is based on two Plasmodium falciparum antigens, CSP and AMA, delivered utilizing GenVec’s adenovector technology and produced using the 293-ORF6 production cell line. The vaccine is designed to generate a broad spectrum of immune responses including antibody and cytolytic T cell stimulation. The approach of eliciting a broad spectrum immune response and attacking multiple stages of the malaria life cycle has shown promise in pre-clinical animal models.
GenVec and NMRC
In October 2012, GenVec signed an agreement worth approximately $3.5 million with the Naval Medical Research Center (NMRC) to support malaria vaccine development.
Under the terms of the agreement, GenVec is responsible for producing clinical supplies of its malaria vaccine, which utilizes its novel, proprietary technology. NMRC plans to use this clinical material to assess the safety and efficacy of these next-generation vectored vaccines using the clinical challenge model developed by NMRC and the Walter Reed Army Institute of Research (WRAIR) malaria vaccine programs, which now are unified as the US Military Malaria Vaccine Program (USMMVP). GenVec retains the right to commercialize this novel technology.
Malaria Vaccine (GNVC), NMRC-M3V-Ad-PfCA News
Pink Sheet FDA Performance Tracker: CBER Approvals
Additional information available to subscribers only: